FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

연구 용도로만 사용. 전체 공지 →

스택 라이브러리

Russian Brain Stack

Cognitive Enhancementintermediate

88

상호작용

88
Share
펩타이드

2

일 평균 mcg

900

수준

intermediate

추가됨

May 17, 2026

개요

The Russian Brain Stack is one of the most pharmacologically elegant peptide combinations in the longevity and cognitive optimization space. Both Semax and Selank were developed at the Institute of Molecular Genetics of the Russian Academy of Sciences and have been prescribed in Russia and Eastern Europe for decades for cognitive enhancement, anxiety, and neurological conditions. Their combination earns a synergy score of 88/100. Semax is a synthetic heptapeptide analog of ACTH (adrenocorticotropic hormone) fragment 4-7. It powerfully upregulates BDNF (Brain-Derived Neurotrophic Factor) — the primary growth factor for neurons — and enhances dopaminergic and serotonergic signaling. The practical effects are significant: improved focus, working memory, learning speed, and mental clarity. It also demonstrates neuroprotective properties, reducing oxidative stress and inflammation in neural tissue. Selank is a synthetic analog of the endogenous tetrapeptide tuftsin, with added stability for intranasal delivery. It modulates GABA signaling and serotonin systems to produce anxiolytic (anti-anxiety) effects without sedation or dependence. Unlike benzodiazepines, Selank does not impair cognition — it enhances it while reducing the anxiety and stress that typically interfere with focus and performance. The synergy is complementary by design: Semax provides the cognitive upregulation (BDNF, focus, memory) while Selank provides the anxiolytic stabilization (calm, reduced cortisol reactivity, stress resilience). Together, they produce a state of calm, focused, high-performance cognition — alertness without anxiety, focus without jitteriness — that neither achieves alone. Both are administered intranasally, which provides efficient CNS delivery without first-pass metabolism.

용량 프로토콜

Semax

Every day· intranasal

Semax에 대한 자세한 내용 →

600 mcg

1회 용량당

Selank

Every day· intranasal

Selank에 대한 자세한 내용 →

300 mcg

1회 용량당

목표 및 증거

Focus and concentrationMemory and learningAnxiety reductionCalm cognitionNeuroplasticity
증거 등급:인체 데이터

경고

  • Semax and Selank are prescription medications in Russia. Regulatory status varies by country. Not FDA-approved in the US.

Comments

Sign in to join the discussion

주의: 이 스택은 커뮤니티에서 제출된 것이며 연구용으로만 사용됩니다. Peptide Contacts는 제출된 스택의 안전성이나 효능을 검증하지 않습니다. 펩타이드 프로토콜을 사용하기 전에 항상 자격이 있는 의료 전문가와 상의하세요.